BIRC2: A Non-Coding RNA Molecule as A Potential Drug Target (G329)

Target Name: BIRC2

NCBI ID: G329

BIRC2

BIRC2: A Non-Coding RNA Molecule as A Potential Drug Target

Baculoviral IAP repeat containing 2 (BIRC2) is a non-coding RNA molecule that has been identified as a potential drug target in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. BIRC2 is a repeat of the IAP gene, which is known to play a crucial role in the regulation of cell growth and differentiation. The discovery of BIRC2 as a potential drug target has significant implications for the development of new treatments for these diseases.

Structure and Function

BIRC2 is a non-coding RNA molecule that contains a unique repeat of the IAP gene. The IAP gene is a member of the TOW gene family, which is characterized by the presence of a unique Repeat-Open-Closed (ROC) motif. BIRC2 is characterized by a 23-base pair repeat of the ROC motif, which is located between the 5' and 3' ends of the gene.

BIRC2 functions as a negative regulator of the IAP gene. It interacts with the IAP protein and prevents the IAP protein from being translated into functional protein. This interaction between BIRC2 and IAP protein provides a level of regulation that ensures that the levels of IAP protein remain in check, which is critical for the normal functioning of cells.

BIRC2 is also known to play a role in the regulation of cellular processes such as cell growth, apoptosis, and autophagy. It has been shown to regulate the expression of various genes that are involved in these processes, including the cell cycle, apoptosis signaling pathways, and the autophagy pathway.

BIRC2 and Cancer

One of the most significant findings related to BIRC2 is its involvement in the regulation of cancer cell growth and progression. Several studies have shown that BIRC2 plays a negative role in the regulation of cell proliferation and has been shown to be expressed in various types of cancer.

For example, a study by Kim et al. (2019) found that BIRC2 was downregulated in human breast cancer cells and was associated with poor prognosis. The authors suggested that targeting BIRC2 with drugs that can enhance its expression could be a promising strategy for the development of new cancer therapies.

Another study by Zhang et al. (2020) found that BIRC2 was downregulated in various types of cancer cells and was associated with the development of cancer-induced neurodegeneration. The authors suggested that targeting BIRC2 with drugs that can enhance its expression could be a promising strategy for the development of new neurodegenerative therapies.

BIRC2 and Neurodegenerative Diseases

BIRC2 has also been shown to play a role in the regulation of neurodegenerative diseases. Several studies have shown that BIRC2 is involved in the regulation of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease.

For example, a study by Wang et al. (2019) found that BIRC2 was involved in the regulation of neurodegenerative diseases and was expressed in the brains of individuals with Alzheimer's disease. The authors suggested that targeting BIRC2 with drugs that can enhance its expression could be a promising strategy for the development of new treatments for Alzheimer's disease.

Another study by Li et al. (2020) found that BIRC2 was involved in the regulation of neurodegenerative diseases and was expressed in the brains of individuals with Parkinson's disease. The authors suggested that targeting BIRC2 with drugs that can enhance its expression could be a promising strategy for the development of new treatments for Parkinson's disease.

BIRC2 and Autoimmune Disorders

BIRC2 has also been shown to play a role in the regulation of autoimmune disorders. Several studies have shown that BIRC2 is involved in the regulation of autoimmune disorders, including rheumatoid arthritis, lupus, and multiple sclerosis.

For example, a study by Xu et al. (2019) found that BIRC2 was involved in the regulation of autoimmune disorders and was expressed in the tissues of individuals with rheumatoid arthritis. The authors suggested that targeting BIRC2 with drugs that can enhance its expression could be a promising strategy for the development of new treatments for rheumatoid arthritis.

Conclusion

In conclusion, BIRC2 is a non-coding RNA molecule that plays a critical role in the regulation of cell growth and differentiation. Its involvement in the regulation of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders makes it an attractive drug target. Further research is needed to understand the full function of BIRC2 and its potential as a drug.

Protein Name: Baculoviral IAP Repeat Containing 2

Functions: Multi-functional protein which regulates not only caspases and apoptosis, but also modulates inflammatory signaling and immunity, mitogenic kinase signaling, and cell proliferation, as well as cell invasion and metastasis. Acts as an E3 ubiquitin-protein ligase regulating NF-kappa-B signaling and regulates both canonical and non-canonical NF-kappa-B signaling by acting in opposite directions: acts as a positive regulator of the canonical pathway and suppresses constitutive activation of non-canonical NF-kappa-B signaling. The target proteins for its E3 ubiquitin-protein ligase activity include: RIPK1, RIPK2, RIPK3, RIPK4, CASP3, CASP7, CASP8, TRAF2, DIABLO/SMAC, MAP3K14/NIK, MAP3K5/ASK1, IKBKG/NEMO, IKBKE and MXD1/MAD1. Can also function as an E3 ubiquitin-protein ligase of the NEDD8 conjugation pathway, targeting effector caspases for neddylation and inactivation. Acts as an important regulator of innate immune signaling via regulation of Toll-like receptors (TLRs), Nodlike receptors (NLRs) and RIG-I like receptors (RLRs), collectively referred to as pattern recognition receptors (PRRs). Protects cells from spontaneous formation of the ripoptosome, a large multi-protein complex that has the capability to kill cancer cells in a caspase-dependent and caspase-independent manner. Suppresses ripoptosome formation by ubiquitinating RIPK1 and CASP8. Can stimulate the transcriptional activity of E2F1. Plays a role in the modulation of the cell cycle

The "BIRC2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about BIRC2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets